Russia has announced a breakthrough in cancer therapy with the Enteromix Cancer Vaccine, an mRNA-based treatment that showed 100% efficacy in early clinical trials for colorectal cancer. This Russian cancer vaccine, unlike chemotherapy, enables the immune system to attack cancer cells directly. Personalised for each patient’s tumor, Enteromix caused tumor shrinkage without serious side effects, offering hope for safer and targeted cancer treatment. If validated in larger trials, it could transform global oncology practices.
🚨🇷🇺💉Russian scientists unveil mRNA cancer vaccine ready for use
The Russian Enteromix cancer vaccine is now ready for clinical use, the Federal Medical and Biological Agency (FMBA) has announced.
FMBD head Veronica Skvortsova said the mRNA-based vaccine had successfully… pic.twitter.com/Q91FTK4obk
— Sputnik (@SputnikInt) September 6, 2025
Enteromix Cancer Vaccine
What makes the Enteromix Vaccine different is its patient-specific design. Each dose is crafted based on the patient’s tumor genetics, increasing precision and effectiveness. In trials with 48 volunteers, tumors shrank significantly while patients avoided harsh side effects. Built on mRNA technology like COVID-19 vaccines, this Russian cancer vaccine can be adapted quickly for other cancers, offering a flexible and next-generation immunotherapy approach.
Russian Cancer Vaccine Trial
The success of Enteromix has global implications. For countries such as India, where colorectal and cervical cancer rates are high, a personalised, safe vaccine could save countless lives. Challenges remain, including production, genomic profiling, and cold-chain logistics, but the promise of this Russian vaccine is clear. With more trials and approval, Enteromix could offer safer, targeted cancer care.
